Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to $680229.2.

  • Molecular Partners Ag's Cash from Financing Activities rose 410.07% to $680229.2 in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year increase of 138073.7%. This contributed to the annual value of $16.4 million for FY2024, which is 134701.51% up from last year.
  • Latest data reveals that Molecular Partners Ag reported Cash from Financing Activities of $680229.2 as of Q3 2025, which was up 410.07% from -$657935.5 recorded in Q2 2025.
  • Molecular Partners Ag's Cash from Financing Activities' 5-year high stood at $57.0 million during Q2 2021, with a 5-year trough of -$56.6 million in Q3 2021.
  • Over the past 5 years, Molecular Partners Ag's median Cash from Financing Activities value was -$321.11 (recorded in 2023), while the average stood at $3.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 52364.08% in 2023, then surged by 135331.18% in 2024.
  • Quarter analysis of 5 years shows Molecular Partners Ag's Cash from Financing Activities stood at $54.8 million in 2021, then crashed by 102.97% to -$1.6 million in 2022, then grew by 19.27% to -$1.3 million in 2023, then surged by 1353.31% to $16.5 million in 2024, then crashed by 95.87% to $680229.2 in 2025.
  • Its Cash from Financing Activities stands at $680229.2 for Q3 2025, versus -$657935.5 for Q2 2025 and -$335.9 for Q1 2025.